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The Innovative Medicines Initiative–funded COMBACTE consortium fosters academic-industry partnership in pioneering studies
to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies,
MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
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Bacterial pneumonia, especially that occurring within the hos-
pitalized or intensive care unit (ICU) population, is a clinically
relevant and serious disease caused by both antibiotic-resistant
and -susceptible strains. The infection contributes significantly
to morbidity and mortality, increases ICU and hospital length
of stay, and represents a substantial economic burden [1, 2].
In the United States and Europe, nosocomial bacterial pneumo-
nia, or hospital-acquired pneumonia (HAP), constitutes one of
the leading nosocomial infections [3, 4], despite numerous
guidelines, international recommendations, and increasing
adoption of ventilator-associated pneumonia (VAP) prevention
care bundles—a series of interventions related to ventilator care
that, when implemented together, will achieve significantly bet-
ter outcomes than when implemented individually [5, 6]. Me-
chanical ventilation (MV) is the most significant risk factor
for nosocomial pneumonia [7–13]. VAP, defined as pneumonia
occurring >48 hours after patients have been intubated and re-
ceived MV, is reported to affect up to 28% of patients on MV
[4], with a reported attributable mortality of 13% [14].
In addition to the VAP care bundles and other prevention
approaches (oral decontamination, weaning protocols, sedation
holidays, etc), current VAP management consists mainly of an-
tibiotic treatment once there is disease progression. Both Staph-
ylococcus aureus (Sa) and Pseudomonas aeruginosa (Pa) are the
bacteria most frequently responsible for VAP [15, 16], and Pa
is one of the most adaptive in developing multidrug resistance
[4]. The loss of effective antibiotics undermines the ability to
manage complications due to infections in vulnerable patient
populations, including critically ill patients. However, novel an-
timicrobial agents and real-time diagnostic techniques have the
potential to modify the management of VAP in the ICU and
could soon result in new preventive approaches [17].
HAP/VAP DIAGNOSTIC ISSUES
Across the many commonly used definitions for VAP, it is gen-
erally agreed that VAP should be diagnosed using a combina-
tion of clinical, laboratory, radiographic, and microbiological
criteria; however, diagnosing VAP remains problematic due to
the lack of sensitivity and specificity of these criteria. For exam-
ple, interpretation of chest radiographs is inherently variable,
and some of the specific clinical signs and symptoms are subjec-
tive and may be inconsistently documented. Therefore, the dis-
tinction between asymptomatic carriage of bacteria in the
respiratory tract and symptomatic bacterial infection is difficult,
often leading to faulty assessments that impact the validity and
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reliability of surveillance data and clinical trial findings. As a
result, a number of different approaches have been proposed
to improve surveillance processes [18–21]. In addition, the
European Medicines Agency (EMA) and the US Food and
Drug Administration (FDA) have developed guidance aimed
at standardizing therapeutic approaches and harmonizing
HAP/VAP definitions and endpoints for industry-sponsored
clinical trials [22–24].
CURRENT PROPHYLAXIS AND PREEMPTIVE
APPROACHES IN HAP/VAP
None or very few other prophylactic strategies show definitive
effectiveness in the real-world environment. The systematic
prophylactic use of antibiotics to prevent VAP can be associated
with some adverse consequences such as emergence of resis-
tance [18]. In patients nasally colonized with Sa, mupirocin re-
duces bacterial carriage, but its direct impact on VAP incidence
remains to be clearly demonstrated and resistance to this com-
pound has been reported [25]. Selective digestive decontamina-
tion and selective oropharyngeal decontamination effectively
reduce the incidence of VAP [26] and improve patient outcome
in settings with low levels of antibiotic resistance [27–29];
however, there is uncertainty as to whether these beneficial out-
comes can be achieved in settings with high levels of antibiotic
resistance. The use of the oral antiseptic chlorhexidine has been
shown to decrease the incidence of VAP with favorable safety
profile and cost considerations [30], cardiac patients possibly
benefiting the most [31]. The use of specific endotracheal
tubes has shown conflicting results on VAP incidence and tra-
cheal colonization, and therefore, these also remain an unproven
strategy [32].
NOVEL PROPHYLACTIC AND PREEMPTIVE
STRATEGIES IN HAP/VAP
A move toward innovative prevention approaches that employ
novel anti-infective agents could enable a change from the cur-
rent “late treatment approach” paradigm and decrease the use
of antibiotics. Preemptive strategies targeting a well-defined
population at higher risk of HAP/VAP could be an intermediate
approach between early antibiotic prophylaxis, which will
increase antimicrobial resistance selection pressure, and delayed
treatment, which may worsen clinical outcomes. Because coloni-
zation of the upper and lower respiratory tract in ICU patients on
MV precedes the development of infection in all cases [33–35],
this population is an ideal target for preemptive strategies given
before the clinical manifestations of pneumonia become evident.
Probiotics could be used as prophylaxis, but trials with pos-
itive results were underpowered to make this conclusive [36].
Appropriate antibiotherapy when given in cases of ventilator-
associated tracheobronchitis (VAT) may decrease the incidence
of VAP [37]. Aerosolized adjunctive therapy using antibiotics
(even started prophylactically) could also represent an interesting
alternative option to intravenous antibiotics in VAT [38, 39]. As
another approach, several vaccines are being evaluated in the
ICU population, but such a preventive approach has yet to be
shown efficacious [40].
POTENTIAL BENEFIT OF MONOCLONAL
ANTIBODIES FOR MANAGING NOSOCOMIAL
INFECTIONS
Because antibiotic options for the treatment of infections
caused by multidrug-resistant bacteria are more and more lim-
ited, there is a medical need for treatment approaches that are
independent of antibiotic susceptibility. In the continuing effort
to identify viable alternatives, antibodies (Abs) are emerging as
a potential choice. Monoclonal antibodies (mAbs) represent an
attractive alternative to antibiotics, for either prophylaxis or pre-
emptive therapy, because of their safety profile, specificity,
mechanism of action, long half-life, and potential to reduce an-
tibiotic use. Investigational mAbs have already been used suc-
cessfully in the ICU as adjunctive therapy in patients with
Pseudomonas VAP [41] with a positive signal on clinical reso-
lution. The first trial evaluating the preemptive use of an mAb
targeting PcrV in Pa yielded a decrease in the incidence of in-
fectious events in patients on MV [42].
PUBLIC–PRIVATE PARTNERSHIPS FOR NEW
ANTIBACTERIAL STRATEGIES
The Combatting Bacterial Resistance in Europe groups
(COMBACTE-NET for gram-positive infections and COMBACTE-
MAGNET for gram-negative infections) are 2 consortia of 8
pharmaceutical industry partners and 51 academic partners
(to date) that have evolved as part of a project developed under
the Innovative Medicines Initiative to address the concerns of in-
creased antibacterial resistance [43]. The focus of these consortia
is to design and implement clinical trials specifically in the area of
HAP/VAP, including preventive and novel therapeutic approach-
es and investigation of novel agents that have the potential to treat
multidrug-resistant pathogens. Within these consortia, COM-
BACTE CLIN-net and COMBACTE LAB-net are the networks
that focus on clinical and laboratory research, respectively.
Thus, the consortia bring together those who are in the forefront
in their area of expertise, allowing for the conduct of high‐quality
research in the areas of epidemiology, prevention, and treatment
of infections.
SAATELLITE AND EVADE STUDIES AND DESIGN
CONSIDERATIONS
Two trials are currently under way within COMBACTE to eval-
uate the benefits of mAbs in ventilated subjects at risk for devel-
oping Sa or Pa pneumonia (Table 1). MEDI4893, an mAb that
binds Sa alpha toxin (AT) and prevents AT pore formation in
target cell membranes [44], is being studied in the SAATELLITE
(A Human Monoclonal Antibody Against Staphylococcus aureus
Alpha Toxin in Mechanically Ventilated Adult Subjects) study.
MEDI3902, a bivalent bispecific mAb that selectively binds to
both the PcrV protein and Psl exopolysaccharide on the sur-
face of Pa, is being studied in EVADE (Effort to Prevent Nos-
ocomial Pneumonia Caused by Pseudomonas aeruginosa in
Mechanically Ventilated Subjects). Binding to PcrV on intact
Pa blocks type 3 secretion injectisome-mediated cytotoxicity
and damage to host cells. Binding to Psl mediates opsonopha-
gocytic killing of Pa by host effector cells and inhibits Pa at-
tachment to host epithelial cells [45]. The preventive
modalities of both Abs are such that they could supplement
the current standard of care for the prevention of nosocomial
pneumonia, including other infection control practices.
Designing prevention studies is particularly challenging as
these are new territory for antimicrobial drug development.
EMA and FDA guidance for the development of products in-
tended to treat nosocomial pneumonia are available and have
been considered in designing the clinical studies for MEDI4893
and MEDI3902 [22, 23, 46]; however, these documents provide
limited guidance for developing prophylactic medicines intended
to prevent nosocomial pneumonia. As such, early input from
both EMA and FDAwas essential to the trial designs, definitions,
and clinical endpoints.
UNIQUE ASPECTS OF THE STUDIES AND STUDY
CONDUCT
Consultation Process in the Collaboration
One of the strengths of the COMBACTE consortium is that it
merges expertise and capabilities from basic science and clinical
research experts in the field of infectious disease and critical care,
thereby optimizing the interaction of experts. Accordingly, instead
of the traditional study designed by a sponsor, with limited scien-
tific input through advisory boards, both SAATELLITE and
EVADE have been built by a working group within the consor-
tium, including not only the clinical experts and the Sponsor
(MedImmune), but also microbiologists to take advantage of
this innovative public–private partnership to address several im-
portant microbiological, clinical, immunological, biological, and
biomarker questions.
Table 1. Efficacy Endpoint of Nosocomial Pneumonia in the Clinical Trials Using MEDI4893 and MEDI3902
Endpoint
SAATELLITE Study (MEDI4893) (A Human Monoclonal
Antibody Against Staphylococcus aureus Alpha Toxin in
Mechanically Ventilated Adult Subjects)
EVADE Study (MEDI3902) (Effort to Prevent
Nosocomial Pneumonia Caused by Pseudomonas
aeruginosa in Mechanically Ventilated Subjects)
Trial A phase 2 randomized, double-blind, placebo-
controlled, single-dose, dose-ranging study of the
efficacy and safety of MEDI4893, in MV adult
subjects colonized with Sa.
A phase 2 proof-of-concept study to evaluate the
efficacy and safety of MEDI3902 in MV colonized
patients for the prevention of nosocomial
pneumonia caused by Pa.
Primary efficacy endpoint The incidence of Sa pneumonia through 30 d after a
single dose of MEDI4893 in MV subjects at risk for
Sa pneumonia.
The incidence of nosocomial pneumonia caused by Pa
through 21 d postdose after a single dose of
MEDI3902 in MV subjects at risk for Pa nosocomial
pneumonia.
Definition of MV and non-MV MV: Subject is intubated with an endotracheal or nasotracheal tube and receiving positive pressure ventilation
support, or subject is not intubated with an endotracheal or nasotracheal tube, but requires ≥8 h of positive
pressure ventilation.
Non-MV: Not mechanically ventilated is defined as not having an endotracheal or nasotracheal tube or requiring
positive pressure ventilation support for at least 8 h.
Radiological, clinical, and microbiologic criteria
to be met concurrently for the endpoint of
pneumonia in MV and non-MV Subjects
Radiographic confirmation for both MV and non-MV subjects: New or worsening infiltrate consistent with
pneumonia on chest radiograph obtained within 24 h of the event (diagnosed by a qualified radiologist).
Clinical confirmation for MV subjects: At least 2 of the following minor or 1 major sign or symptoms of new onset:
• Minor criteria: (1) systemic signs of infection (1 or more of the following): abnormal temperature and/or
abnormal WBC count; (2) production of new purulent endotracheal secretions; (3) new physical examination
findings consistent with pneumonia/pulmonary consolidation.
• Major criteria: acute changes made in the ventilatory support system to enhance oxygenation, as determined
by partial oxygen pressure.
Clinical confirmation for non-MV subjects: At least 2 of the following minor or 1 major signs or symptoms:
• Minor criteria: (1) systemic signs of infection: Abnormal temperature and/or abnormal WBC; (2) a new onset of
cough (or worsening of cough); (3) production of purulent sputum; (4) physical examination findings consistent
with pneumonia/pulmonary consolidation; (5) dyspnea, tachypnea, or hypoxemia.
• Major criteria: a need to initiate noninvasive mechanical ventilation or reinitiate invasive mechanical ventilation
because of respiratory failure or worsening of respiratory status.
Microbiologic confirmation for MV subjects: At least 1 of the following obtained within 24 h of onset of the event:
• Lower respiratory specimen positive for Sa (for SAATELLITE) and Pa (for EVADE) by culture.
• Blood culture positive for Sa (for SAATELLITE) and Pa (for EVADE) (and no apparent primary source of infection
outside the lung).
• Pleural fluid aspirate or lung tissue culture positive for Sa (for SAATELLITE) and Pa (for EVADE) during episode
of pneumonia (only if obtained as part of the subject’s necessary clinical management).
Microbiologic confirmation for non-MV subjects: Same as MV subjects but respiratory sample to also include
expectorated sputum; a culture may be obtained within 72 h of onset of the event.
Abbreviations: MV, mechanically ventilated; Pa, Pseudomonas aeruginosa; Sa, Staphylococcus aureus; WBC, white blood cell.
Selection of Endpoints That Are Clinically Meaningful and
Reproducible
Whereas clinical resolution of the infection and reduction in
mortality remain the standard primary endpoints in the classical
noninferiority VAP treatment trial, prevention of the onset of
VAP is proposed as a preemptive approach using mAbs. To con-
duct meaningful clinical trials, MedImmune and COMBACTE
partners had to develop and adapt existing definitions for VAP
diagnosis to a definition of Sa and Pa pneumonia for the primary
endpoint assessment. The definition was based on objective and
reproducible clinical, laboratory, radiographic, and microbiologic
criteria, and was meant to be reproducible and consistently im-
plemented by all investigators participating in the efficacy studies.
The primary efficacy endpoint of nosocomial pneumonia and its
definition are shown in Table 1.
While all study subjects will be on MV at the time of enroll-
ment and a substantial number of subjects will likely continue to
require MV throughout the postdose period, some will be suc-
cessfully weaned during this period but may still develop pneu-
monia after extubation. Therefore, primary efficacy will be
evaluated in subjects who remain on MV as well as those extu-
bated and no longer requiring MV through the follow-up periods
of 30 and 21 days for MEDI4893 and MEDI3902, respectively.
In both studies, pneumonia will be identified at the bedside
by the physician responsible for the subject, but every event will
then be confirmed by an endpoint adjudication committee. This
committee—consisting of an independent group of experts se-
lected by the COMBACTE consortium, including the sponsor
—will review blinded data reported by trial investigators to de-
termine whether the endpoints meet protocol-specified criteria.
With approximately 900 subjects targeted in both SAATEL-
LITE and EVADE, secondary endpoints should generate a large
volume of information that may benefit future programs. These
trials, coupled with an epidemiology ASPIRE study (Advanced
Understanding of Sa and Pa Infections in Europe), also con-
ducted within the COMBACTE consortium, will generate
data on Sa and Pa colonization in patients on MV that should
advance our knowledge in treating patients.
Use of Real-time Techniques to Detect Colonization
For both trials, a species-specific real-time diagnostic assay will be
used to screen for Sa or Pa colonization before onset of any in-
fection. Endotracheal aspirate will be screened by polymerase
chain reaction for Sa or Pa, respectively, using Sa- or Pa-specific
tests developed by Cepheid Diagnostics (Sunnyvale, California)
[47]. These rapid molecular diagnostics require <5 minutes of
hands-on time, can be performed routinely and easily (even po-
tentially at the bedside), and have been developed to identify col-
onized patients. The Sa test identifies bothmethicillin-susceptible
and methicillin-resistant Sa using an existing skin and soft tissue
infection test system that has been adapted for use with lower re-
spiratory tract samples. Within 90 minutes of sampling, respira-
tory tract colonization with Sa or Pa is confirmed. This is the first
time that a complementary rapid diagnostic is being used to iden-
tify colonized patients in the ICU in a VAP prevention trial. With
the rapid advances in molecular biology and instrumentation,
these assays could pave the way for a new paradigm in identifying
high-risk patients and providing prophylaxis or preemptive treat-
ment for other serious bacterial infections such as Acinetobacter
baumannii and Klebsiella pneumoniae.
Ancillary Biomarker Program
The COMBACTE consortia programs also offer a unique op-
portunity to help characterize pathogen virulence factors, the
host immune system, and other host factors that facilitate path-
ogen-induced disease and/or play a role in the host response to
colonization and infection. Establishing a comprehensive bio-
marker strategy, as ancillary research studies to SAATELLITE
and EVADE, is a cornerstone of this public–private consortia,
and translational, epidemiological, and basic research per-
formed by some of the leading laboratories in Europe will gen-
erate new insights into the host–pathogen relationship and
provide new knowledge for future antibiotic, mAb, and vaccine
development. In both studies, the opsonophagocytic killing ac-
tivity in serum and serum Abs against bacterial virulence factors
will be measured. In SAATELLITE, this includes measuring
AT-specific serum immunoglobulin G (IgG) and AT serum
neutralizing Abs, as well as a panel of 75 other virulence factors
of Sa. Subsequently, more in-depth immunological and clinical
analyses will be performed to determine correlates of protection.
This includes characterizing the complete immune-proteome
against all Sa antigens with select samples by 2Dgel/Western
blot analysis. An in-depth analysis of Abs against nonprotein
cell wall structure quantification of the contribution of the 4
IgG-evasion molecules (SpA, SSL10, SBI, and FLIPr) will be per-
formed. For EVADE, serum Ab levels against PcrV and Psl will
be performed at baseline and over time in subjects with and with-
out microbiologically confirmed Pa infection. Levels of Psl and
PcrV will be characterized on Pa isolates from the EVADE
study, and the levels of secreted AT will be determined on meth-
icillin-susceptible and methicillin-resistant Sa isolates from the
SAATELLITE study. In both the SAATELLITE and EVADE clin-
ical studies and the ASPIRE epidemiology study, a complete anti-
biogram will be performed on the isolates to gain a better
understanding of the incidence and prevalence of antibiotic resis-
tance in ICUs, and whole-genome sequencing of Sa and Pa will
be performed to fully characterize the resistome and toxome of
the bacterial species. Last, levels of host inflammatory biomarkers
in blood, serum, and respiratory samples will be determined to
identify patients at greatest risk of developing pneumonia, sepsis,
or other complications from bacterial colonization or infection.
CONCLUSIONS
The standard of care for prevention of Sa and Pa infection in pa-
tients on MV relies primarily on the implementation of hospital
infection control methods, which historically have been shown to
produce varying levels of sustained success, never reaching com-
plete prevention or control. Adaption of new preventive modal-
ities, such as pathogen-specific mAbs, may augment success
rates, but will require a shift in the strategy of treating and man-
aging high-risk patients to prevent serious Sa and Pa infections.
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